Ditchcarbon
  • Contact
  1. Organizations
  2. Insilico Medicine, Inc.
Public Profile
Business Services
HK
updated 22 days ago

Insilico Medicine, Inc. Sustainability Profile

Company website

Insilico Medicine, Inc., a pioneering biotechnology firm headquartered in Hong Kong, is at the forefront of artificial intelligence-driven drug discovery and development. Founded in 2014, the company has rapidly established itself as a leader in the industry, leveraging advanced machine learning techniques to accelerate the drug development process. With a focus on areas such as ageing research and disease modelling, Insilico Medicine offers unique solutions that integrate AI with biology, enabling the identification of novel drug candidates and biomarkers. The company’s innovative platform has garnered significant attention, leading to partnerships with major pharmaceutical firms and academic institutions. Recognised for its contributions to the field, Insilico Medicine continues to push the boundaries of traditional drug discovery, positioning itself as a key player in the evolving landscape of biotechnology.

DitchCarbon Score

How does Insilico Medicine, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

20

Industry Average

Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

26

Industry Benchmark

Insilico Medicine, Inc.'s score of 20 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.

29%

Let us know if this data was useful to you

Insilico Medicine, Inc.'s reported carbon emissions

Insilico Medicine, Inc., headquartered in Hong Kong, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. As there are no emissions or reduction initiatives reported, it is unclear how Insilico Medicine, Inc. is addressing its carbon footprint or contributing to climate action within the biotechnology sector. The lack of data may suggest an opportunity for the company to develop and communicate its climate commitments more effectively in the future.

How Carbon Intensive is Insilico Medicine, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Insilico Medicine, Inc.'s primary industry is Other business services (74), which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Insilico Medicine, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Insilico Medicine, Inc. is in HK, which we do not have grid emissions data for.

Insilico Medicine, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Insilico Medicine, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Insilico Medicine, Inc.'s Emissions with Industry Peers

Inductive Bio, Inc.

US
•
Research and development services (73)
Updated 17 days ago

Molsoft LLC

US
•
Research and development services (73)
Updated about 2 months ago

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Thermo Fisher Scientific

US
•
Medical, precision and optical instruments, watches and clocks (33)
Updated 10 days ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated about 4 hours ago

Novartis

CH
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy